Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
McKesson
Colorcon
Medtronic

Last Updated: February 7, 2023

EMERPHED Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Emerphed patents expire, and what generic alternatives are available?

Emerphed is a drug marketed by Nexus Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in eight countries.

The generic ingredient in EMERPHED is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Emerphed

A generic version of EMERPHED was approved as ephedrine sulfate by AKORN on March 1st, 2017.

  Try it Free

Paragraph IV (Patent) Challenges for EMERPHED
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EMERPHED Injection ephedrine sulfate 50 mg/10 mL 213407 1 2021-10-14

US Patents and Regulatory Information for EMERPHED

EMERPHED is protected by four US patents.

Patents protecting EMERPHED

Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION

Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nexus Pharms EMERPHED ephedrine sulfate SOLUTION;INTRAVENOUS 213407-001 Apr 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Nexus Pharms EMERPHED ephedrine sulfate SOLUTION;INTRAVENOUS 213407-001 Apr 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Nexus Pharms EMERPHED ephedrine sulfate SOLUTION;INTRAVENOUS 213407-001 Apr 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EMERPHED

See the table below for patents covering EMERPHED around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2020232424 See Plans and Pricing
Israel 288044 תכשירים המכילים אפהרדין או מלח אפהרדין ושיטות להכנתם ולשימוש בהם (Compositions comprising ephedrine or an ephedrine salt and methods of making and using same) See Plans and Pricing
China 113825500 包含麻黄碱或麻黄碱盐的组合物及其制备和使用方法 (COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EMERPHED

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1110543 08C0004 France See Plans and Pricing PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
1110543 SPC/GB08/005 United Kingdom See Plans and Pricing SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
Medtronic
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.